Sotera Health (NASDAQ:SHC) Issues Earnings Results, Beats Expectations By $0.03 EPS

Sotera Health (NASDAQ:SHC) released its quarterly earnings results on Friday. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.03, Briefing.com reports. Sotera Health had a net margin of 2.24% and a return on equity of 41.08%. The business had revenue of $294.34 million for the quarter, compared to analysts’ expectations of $275.81 million. During the same quarter in the previous year, the business posted $0.19 earnings per share. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. Sotera Health updated its FY 2025 guidance to 0.750-0.820 EPS.

Sotera Health Price Performance

Shares of Sotera Health stock opened at $13.97 on Friday. The firm has a market cap of $3.97 billion, a PE ratio of 174.65 and a beta of 1.81. The stock has a 50 day moving average of $11.63 and a 200 day moving average of $12.03. The company has a current ratio of 2.46, a quick ratio of 2.19 and a debt-to-equity ratio of 5.55. Sotera Health has a 12 month low of $9.53 and a 12 month high of $17.08.

Hedge Funds Weigh In On Sotera Health

A number of institutional investors and hedge funds have recently made changes to their positions in SHC. Empowered Funds LLC boosted its stake in shares of Sotera Health by 11.1% during the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after purchasing an additional 2,845 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Sotera Health by 14.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock valued at $3,999,000 after buying an additional 43,471 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock valued at $293,000 after buying an additional 14,018 shares in the last quarter. Finally, Creative Planning boosted its position in Sotera Health by 15.3% in the 2nd quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after buying an additional 2,673 shares during the period. 91.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Piper Sandler reduced their target price on shares of Sotera Health from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 23rd. Barclays reiterated an “overweight” rating on shares of Sotera Health in a report on Friday. The Goldman Sachs Group upgraded Sotera Health from a “neutral” rating to a “buy” rating and upped their price target for the stock from $14.00 to $17.00 in a research note on Monday, May 5th. Finally, Wall Street Zen upgraded Sotera Health from a “hold” rating to a “buy” rating in a research note on Saturday, June 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.